5.92
price down icon12.30%   -0.83
after-market Dopo l'orario di chiusura: 5.94 0.02 +0.34%
loading
Precedente Chiudi:
$6.75
Aprire:
$6.75
Volume 24 ore:
1.76M
Relative Volume:
3.53
Capitalizzazione di mercato:
$364.78M
Reddito:
-
Utile/perdita netta:
$-117.81M
Rapporto P/E:
9.25
EPS:
0.64
Flusso di cassa netto:
$74.30M
1 W Prestazione:
+38.00%
1M Prestazione:
+42.65%
6M Prestazione:
+71.59%
1 anno Prestazione:
+260.98%
Intervallo 1D:
Value
$5.82
$6.75
Intervallo di 1 settimana:
Value
$4.175
$7.51
Portata 52W:
Value
$1.60
$7.51

Omeros Corporation Stock (OMER) Company Profile

Name
Nome
Omeros Corporation
Name
Telefono
206-676-5000
Name
Indirizzo
201 ELLIOTT AVENUE WEST, SEATTLE, WA
Name
Dipendente
198
Name
Cinguettio
@OmerosCorp
Name
Prossima data di guadagno
2024-11-07
Name
Ultimi documenti SEC
Name
OMER's Discussions on Twitter

Confronta OMER con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
OMER 5.92 364.78M 0 -117.81M 74.30M 0.64
VRTX 467.01 119.87B 10.63B -479.80M -1.35B 13.33
REGN 762.00 83.27B 13.85B 4.65B 3.32B 35.06
ARGX 567.90 33.96B 1.86B -40.29M -1.28B -4.16
ALNY 232.27 30.18B 2.09B -332.26M 16.06M -4.14
BNTX 101.87 24.42B 3.30B -501.07M 1.03B 11.54

Omeros Corporation Stock (OMER) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2022-12-08 Downgrade UBS Buy → Neutral
2022-11-08 Downgrade BofA Securities Neutral → Underperform
2022-06-08 Downgrade BofA Securities Buy → Neutral
2021-10-08 Downgrade JP Morgan Neutral → Underweight
2021-10-01 Downgrade Maxim Group Buy → Hold
2021-10-01 Downgrade Wedbush Neutral → Underperform
2021-09-27 Iniziato JP Morgan Neutral
2021-02-01 Iniziato UBS Buy
2020-10-20 Iniziato BofA Securities Buy
2020-08-21 Reiterato H.C. Wainwright Buy
2020-08-14 Reiterato Maxim Group Buy
2019-05-06 Iniziato Cantor Fitzgerald Overweight
2018-07-12 Iniziato Seaport Global Securities Buy
2018-03-23 Downgrade Wedbush Outperform → Neutral
2018-03-05 Downgrade Needham Buy → Hold
2017-11-08 Iniziato H.C. Wainwright Buy
2017-05-11 Downgrade Cantor Fitzgerald Buy → Neutral
2017-03-17 Reiterato Maxim Group Buy
2017-03-17 Reiterato Needham Buy
2016-11-16 Reiterato Wedbush Outperform
2016-11-10 Reiterato Needham Buy
2016-08-10 Reiterato Maxim Group Buy
2016-06-03 Iniziato Cantor Fitzgerald Buy
2016-03-02 Reiterato Needham Buy
2016-02-29 Reiterato Wedbush Outperform
2015-11-11 Reiterato Needham Buy
2015-08-18 Reiterato WBB Securities Strong Buy
2015-08-10 Iniziato ROTH Capital Buy
Mostra tutto

Omeros Corporation Borsa (OMER) Ultime notizie

pulisher
Nov 17, 2024

Omeros Q3 2024Updates On OMIDRIA And Narsoplimab Lead To Liquidity Concerns (OMER) - Seeking Alpha

Nov 17, 2024
pulisher
Nov 16, 2024

Data Storage Corporation Reports 2024 Third Quarter Financial Results and Provides Business UpdateWASHINGTON, D.C. – Data Storage Corporation (NASDAQ: DTST) released its financial results for the third quarter ending September 30, 2024, and provi - Defense World

Nov 16, 2024
pulisher
Nov 16, 2024

SigmaTron International, Inc. Announces Departure and Appointment of Chief Financial OfficerUNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549_______________FORM 8-K_______________CURRENT REPORTPurs - Defense World

Nov 16, 2024
pulisher
Nov 15, 2024

U.S. shares lower at close of trade; Dow Jones Industrial Average down 0.47% - MSN

Nov 15, 2024
pulisher
Nov 15, 2024

Sydney high school parents vent frustration at plan for single-sex schools to become co-educational - ABC News

Nov 15, 2024
pulisher
Nov 15, 2024

Omeros (NASDAQ:OMER) Upgraded at RODMAN&RENSHAW - MarketBeat

Nov 15, 2024
pulisher
Nov 14, 2024

U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.47% - MSN

Nov 14, 2024
pulisher
Nov 14, 2024

United States shares lower at close of trade; Dow Jones Industrial Average down 0.47% - Investing.com India

Nov 14, 2024
pulisher
Nov 14, 2024

Omeros stock soars to 52-week high, hits $5.68 By Investing.com - Investing.com Canada

Nov 14, 2024
pulisher
Nov 14, 2024

Earnings call: Omeros narrows Q3 loss, progresses key drug programs By Investing.com - Investing.com Australia

Nov 14, 2024
pulisher
Nov 14, 2024

Earnings call: Omeros narrows Q3 loss, progresses key drug programs - Investing.com India

Nov 14, 2024
pulisher
Nov 14, 2024

Omeros (OMER) Stock Rises After Reporting Q3Results - Stocks Telegraph

Nov 14, 2024
pulisher
Nov 14, 2024

Omeros Shares Hit 52-Week High on Plan to Resubmit Narsoplimab Application - MarketWatch

Nov 14, 2024
pulisher
Nov 14, 2024

U.S. Stock market top gainers: Omeros Corporation gains 52.99% while InflaRx N.V surges by 40.94% - Business Upturn

Nov 14, 2024
pulisher
Nov 14, 2024

Rodman & Renshaw sets $9 target on Omeros stock with Buy rating - Investing.com

Nov 14, 2024
pulisher
Nov 14, 2024

Omeros' (OMER) "Neutral" Rating Reiterated at Cantor Fitzgerald - MarketBeat

Nov 14, 2024
pulisher
Nov 14, 2024

Omeros stock soars to 52-week high, hits $5.68 - Investing.com

Nov 14, 2024
pulisher
Nov 14, 2024

U.S. Stock market top gainers: AgEagle Aerial Systems surges by 151.55% while Gaxos.ai Inc gains 47.58% in ealry trading - Business Upturn

Nov 14, 2024
pulisher
Nov 14, 2024

Needham & Company LLC Reaffirms "Hold" Rating for Omeros (NASDAQ:OMER) - MarketBeat

Nov 14, 2024
pulisher
Nov 14, 2024

Omeros initiated with a Buy at Rodman & Renshaw - TipRanks

Nov 14, 2024
pulisher
Nov 14, 2024

Omeros (NASDAQ:OMER) Coverage Initiated by Analysts at Rodman & Renshaw - MarketBeat

Nov 14, 2024
pulisher
Nov 14, 2024

Omeros: Q3 Earnings Snapshot - New Haven Register

Nov 14, 2024
pulisher
Nov 14, 2024

Omeros Corp (OMER) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Adjustments - Yahoo Finance

Nov 14, 2024
pulisher
Nov 13, 2024

Omeros Corporation Q3 2024 Financial Results Reviewed - TipRanks

Nov 13, 2024
pulisher
Nov 13, 2024

Omeros up 4% as Q3 results beat on EPS - MSN

Nov 13, 2024
pulisher
Nov 13, 2024

Omeros reports Q3 EPS (56c), two estimates (70c) - TipRanks

Nov 13, 2024
pulisher
Nov 13, 2024

Q3 2024 Omeros Corp Earnings Call Transcript - GuruFocus.com

Nov 13, 2024
pulisher
Nov 13, 2024

Omeros Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 13, 2024
pulisher
Nov 13, 2024

Omeros Q3 Loss Narrows to $32.2M, Advances Key Drug Programs Amid FDA Talks | OMER Stock News - StockTitan

Nov 13, 2024
pulisher
Nov 13, 2024

Omeros Corporation Reports Third Quarter 2024 Financial Results - The Bakersfield Californian

Nov 13, 2024
pulisher
Nov 13, 2024

Blackline, Inc. Appoints Philippe Omer Decugis as Senior Vice President for Europe - Marketscreener.com

Nov 13, 2024
pulisher
Nov 12, 2024

Earnings Outlook For Omeros - Benzinga

Nov 12, 2024
pulisher
Nov 12, 2024

Omeros (OMER) Scheduled to Post Earnings on Wednesday - MarketBeat

Nov 12, 2024
pulisher
Nov 11, 2024

Omeros (OMER) Sets Q3 2024 Earnings Call for November 13: What to Watch | OMER Stock News - StockTitan

Nov 11, 2024
pulisher
Nov 11, 2024

Week Ahead In Pharmaceuticals: 5 Stocks To Watch (OMER, BOLD, XLRN...) - RTTNews

Nov 11, 2024
pulisher
Nov 06, 2024

Omeros (NASDAQ:OMER) Stock Passes Above 200 Day Moving AverageHere's What Happened - MarketBeat

Nov 06, 2024
pulisher
Oct 31, 2024

Cardiff City board to hold meeting with Omer Riza this weekend - Wales Online

Oct 31, 2024
pulisher
Oct 29, 2024

Atypical Hemolytic Uremic Syndrome Drugs Market 2034: - openPR

Oct 29, 2024
pulisher
Oct 29, 2024

NVIDIA Co. (NASDAQ:NVDA) Stock Holdings Increased by Alpha DNA Investment Management LLC - Defense World

Oct 29, 2024
pulisher
Oct 29, 2024

Omeros (NASDAQ:OMER) Shares Pass Above Two Hundred Day Moving AverageHere's Why - MarketBeat

Oct 29, 2024
pulisher
Oct 28, 2024

Focal Segmental Glomerulosclerosis Drugs Market Report 2024FSGS Drugs Market Size - WhaTech

Oct 28, 2024
pulisher
Oct 25, 2024

Global Atypical Hemolytic Uremic Syndrome (aHUS) Treatment Market to Reach USD 2308.84 Million by 20 - PharmiWeb.com

Oct 25, 2024
pulisher
Oct 25, 2024

Zaltenibart Receives FDA Rare Pediatric Disease Designation for C3 Glomerulopathy - Pharmacy Times

Oct 25, 2024
pulisher
Oct 24, 2024

OMEROmeros Corporation Latest Stock News & Market Updates - StockTitan

Oct 24, 2024
pulisher
Oct 24, 2024

FDA Grants Rare Pediatric Disease Designation to Omeros’ MASP-3 Inhibitor Zaltenibart for Treatment of C3 Glomerulopathy - Business Wire

Oct 24, 2024
pulisher
Oct 22, 2024

Global Alcohol Use Disorder Treatment Market to Reach USD 1,300 million by 2033 at a 6.4% CAGR, Driv - PharmiWeb.com

Oct 22, 2024
pulisher
Oct 22, 2024

Omer Riza wants 'clarity' over Cardiff City manager position exactly one month on from Bulut sacking - Wales Online

Oct 22, 2024
pulisher
Oct 21, 2024

Ischemia Reperfusion Injury Therapeutics Market Generated - openPR

Oct 21, 2024
pulisher
Oct 21, 2024

Next Cardiff City manager latest as Omer Riza now favourite for job - Wales Online

Oct 21, 2024
pulisher
Oct 17, 2024

Omer Arbel Office unveils planned community for Washington State site - The Architect's Newspaper

Oct 17, 2024
pulisher
Oct 17, 2024

OMER (Omeros) Operating Margin % : 0.00% (As of Jun. 2024) - GuruFocus.com

Oct 17, 2024

Omeros Corporation Azioni (OMER) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$18.98
price up icon 3.66%
$76.97
price up icon 1.45%
$39.51
price up icon 7.22%
$359.21
price down icon 1.11%
$187.69
price down icon 0.81%
$101.87
price up icon 2.16%
Capitalizzazione:     |  Volume (24 ore):